Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX)

Ventyx Biosciences, Inc. (NASDAQ:VTYX) saw unusually large options trading activity on Tuesday. Traders acquired 2,207 call options on the company. This is an increase of approximately 299% compared to the average volume of 553 call options.

Hedge Funds Weigh In On Ventyx Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its holdings in Ventyx Biosciences by 376.4% in the 4th quarter. Bank of America Corp DE now owns 4,273,442 shares of the company’s stock valued at $9,359,000 after purchasing an additional 3,376,446 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Ventyx Biosciences in the fourth quarter worth about $3,903,000. Millennium Management LLC grew its stake in shares of Ventyx Biosciences by 369.7% in the fourth quarter. Millennium Management LLC now owns 1,281,629 shares of the company’s stock valued at $2,807,000 after buying an additional 1,008,760 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Ventyx Biosciences by 88.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company’s stock valued at $1,909,000 after buying an additional 409,357 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Ventyx Biosciences by 72.1% during the 4th quarter. Two Sigma Advisers LP now owns 800,800 shares of the company’s stock worth $1,754,000 after acquiring an additional 335,400 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th.

Ventyx Biosciences Stock Performance

Shares of NASDAQ:VTYX opened at $1.07 on Wednesday. The stock has a 50-day simple moving average of $1.60 and a 200-day simple moving average of $2.03. The stock has a market capitalization of $76.11 million, a P/E ratio of -0.45 and a beta of 0.58. Ventyx Biosciences has a 1 year low of $1.07 and a 1 year high of $5.66.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.13. Analysts predict that Ventyx Biosciences will post -2.09 earnings per share for the current year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.